Key result
Pathogenic CYP27A1 variants in monogenic FH link to ~/mL higher cholestanol and thicker Achilles tendons.
Why the study?
Whether pathogenic CYP27A1 variants modify the clinical manifestations of familial hypercholesterolemia arising from defects in the LDL receptor or related genes remained unclear.
Does carrying a pathogenic CYP27A1 variant modify clinical phenotypes (serum cholestanol levels and Achilles tendon thickness) in patients with monogenic heterozygous familial hypercholesterolemia?
Observational (n=644)
No
Does carrying a pathogenic CYP27A1 variant modify clinical phenotypes (serum cholestanol levels and Achilles tendon thickness) in patients with monogenic heterozygous familial hypercholesterolemia?
Answers are grounded in this paper and cite their sources.
In patients with monogenic heterozygous familial hypercholesterolemia, carrying a pathogenic CYP27A1 variant (3.4% prevalence) is significantly associated with elevated serum cholestanol levels and increased Achilles tendon thickness.
Backgrounds Cerebrotendinous xanthomatosis (CTX) is a rare inherited metabolic disorder caused by pathogenic variants in the cytochrome P450 family 27 subfamily A member 1 (CYP27A1) gene. It remains unclear whether such variants modify the clinical manifestations of familial hypercholesterolemia (FH) arising from defects in the low-density lipoprotein (LDL) receptor or related genes. Methods We evaluated 2,011 individuals diagnosed as clinical FH according to the Japanese FH criteria at our hospital between April 1990 and March 2020. Of these, 848 participants without pathogenic variants in FH-related genes and 725 participants lacking phenotypic data and/or genetic analysis were excluded. In addition, six patients with homozygous or compound heterozygous FH were excluded. Ultimately, 644 participants were included in this analysis (male: 52%; female: 48%; mean age: 52 years). Baseline assessments for each participant—including medical history, physical examination, and blood tests—were reviewed. Results Among these individuals, 22 (3.4%) carried a pathogenic CYP27A1 variant. Patients harboring a pathogenic variant showed significantly higher median cholestanol concentrations compared with non-carriers (3.7 vs. 2.3 μg/mL, p < 0.001). A single pathogenic CYP27A1 variant was associated with an increase in serum cholestanol of 2.1 μg/mL (95% confidence interval: 1.2–3.0 μg/mL, p < 0.001). Furthermore, carriers exhibited significantly greater Achilles tendon thickness than non-carriers (9.6 vs. 8.9 mm, p < 0.001). Conclusion We identified a notable proportion of monogenic FH patients who carried a pathogenic CYP27A1 variant, which was associated with increased Achilles tendon thickness and elevated serum cholestanol levels.
No takes yet. Share an insight, caveat, or question.
Tada et al. (2026) conducted an observational in Monogenic heterozygous familial hypercholesterolemia (n=644). Pathogenic CYP27A1 variant carrier status vs. Non-carriers of pathogenic CYP27A1 variants was evaluated on Serum cholestanol concentration (μg/mL) and Achilles tendon thickness (mm) (MD 2.1 μg/mL, 95% CI 1.2-3.0, p=<0.001). Carrying a pathogenic CYP27A1 variant in monogenic FH patients was associated with higher serum cholestanol and greater Achilles tendon thickness.
Synapse has enriched 10 related papers. Consider them for comparative context: